









Markets
/
Stocks
/
nasdaq-bntx
/

Biontech SE

BNTX

104.082USD

+0.732+0.71%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

25.02BMarket Cap

LossP/E TTM



Biontech SE

104.082

+0.732+0.71%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biontech SE

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biontech SE's Score

Industry at a Glance

Industry Ranking

73 / 407

Overall Ranking

173 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 23 analysts

Buy

Current Rating

135.505

Target Price

+29.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Biontech SE Highlights

StrengthsRisks

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -85.33, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 56.09M shares, decreasing 2.95% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 8.04M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 7.71, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 225.41M, representing a year-over-year increase of 91.82%, while its net profit experienced a year-over-year increase of 54.70%.

Score

Industry at a Glance

Previous score

7.71

Change



Financials

9.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Biontech SE's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 8.27, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -85.33, which is -367.45% below the recent high of 228.22 and -11.57% above the recent low of -95.21.

Score

Industry at a Glance

Previous score

8.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 73/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 7.91, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Biontech SE is 136.50, with a high of 185.00 and a low of 82.11.

Score

Industry at a Glance

Previous score

7.91

Change

Support & Resistance

No Data

Analyst Rating

Based on 23 analysts

Buy

Current Rating

135.505

Target Price

+29.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

Biontech SE

BNTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 6.62, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 108.39 and the support level at 99.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.21

Change

-0.59

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.175

Neutral

RSI(14)

47.424

Neutral

STOCH(KDJ)(9,3,3)

28.564

Sell

ATR(14)

3.093

Low Volatility

CCI(14)

-37.431

Neutral

Williams %R

73.112

Sell

TRIX(12,20)

0.174

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

104.968

Sell

MA10

105.613

Sell

MA20

104.971

Sell

MA50

103.012

Buy

MA100

106.318

Sell

MA200

105.936

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 23.33%, representing a quarter-over-quarter decrease of 72.68%. The largest institutional shareholder is Baillie Gifford, holding a total of 8.04M shares, representing 3.34% of shares outstanding, with 2.38% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

AT Impf GmbH

101.85M

-0.62%

Medine GmbH

40.13M

-0.75%

Baillie Gifford & Co.

Star Investors

8.04M

-1.48%

Fidelity Management & Research Company LLC

6.98M

+17.22%

Flossbach von Storch AG

4.23M

-0.69%

PRIMECAP Management Company

Star Investors

4.00M

-1.11%

Pfizer Inc

3.66M

T. Rowe Price Investment Management, Inc.

3.60M

+4076.79%

Sahin (Ugur MD)

2.05M

-26.11%

Temasek Holdings Pte. Ltd.

1.51M

-16.67%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 6.78, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.